This mechanism makes ligelizumab a promising candidate for treating allergic diseases characterized by IgE-mediated inflammation, including chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), food allergies, and asthma [103]. The gene discussed is IGHE; the disease is allergic disease.